https://www.selleckchem.com/products/dnqx.html
Biosimilars, or highly similar versions of complex biologic drugs, have the potential to slow drug spending growth; however, biosimilar uptake in the United States has been slow. Little is known about barriers to biosimilar uptake following drug launch. To examine the patient, physician, and practice characteristics associated with biosimilar use in the Medicare population. This cross-sectional study used regression analysis to estimate the association between biosimilar use and various characteristics. Medicare fee-for-service beneficiari